ArQule said today it will combine its chemistry and drug development expertise with the discovery platforms of Beryllium Discovery in a collaboration to identify and validate targets for new small-molecule immune-oncology treatments.

The value of the companies’ collaborative R&D agreement was not disclosed.

The companies said they will pursue targets that include PD-1 (programmed cell death protein 1) and PDL-1 (programmed death ligand 1)—two targets for which numerous drug developers are pursuing immunotherapies, according to a recent GEN List.

ArQule and Beryllium reason that molecules that bind to and inhibit the effects of these targets may help direct the immune system to combat a variety of tumors.

“We are excited by the potential synergy in combining complementary technologies and expertise to pursue cost-effective, shared-risk development pathways for the selection of compounds identified from ArQule’s small molecule library or rationally designed through Beryllium’s fragment-based research capabilities and ArQule chemistry technology,” ArQule CMO Brian Schwartz said in a statement.

ArQule focuses on small-molecule cancer therapeutics; its lead product, tivantinib (ARQ 197), is an oral, selective inhibitor of the c-MET receptor tyrosine kinase that is in Phase II/III clinical development. Until now, ArQule’s discovery efforts have been focused on identifying new kinase inhibitors, by leveraging its library of compounds.








This site uses Akismet to reduce spam. Learn how your comment data is processed.